162 related articles for article (PubMed ID: 23147696)
1. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial.
Yokoyama K; Hirakata H; Akiba T; Sawada K; Kumagai Y
Am J Nephrol; 2012; 36(5):478-87. PubMed ID: 23147696
[TBL] [Abstract][Full Text] [Related]
2. JTT-751 for treatment of patients with hyperphosphatemia on peritoneal dialysis.
Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Hirakata H
Nephron Clin Pract; 2014; 128(1-2):135-40. PubMed ID: 25401266
[TBL] [Abstract][Full Text] [Related]
3. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
[TBL] [Abstract][Full Text] [Related]
4. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kanoh H
Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.
Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
Nephrol Dial Transplant; 2014 May; 29(5):1053-60. PubMed ID: 24376274
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis.
Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
J Ren Nutr; 2014 Jul; 24(4):261-7. PubMed ID: 24836401
[TBL] [Abstract][Full Text] [Related]
7. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
[TBL] [Abstract][Full Text] [Related]
8. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
Koiwa F; Terao A
Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
[TBL] [Abstract][Full Text] [Related]
9. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
[TBL] [Abstract][Full Text] [Related]
10. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study.
Lee CT; Wu IW; Chiang SS; Peng YS; Shu KH; Wu MJ; Wu MS
J Nephrol; 2015 Feb; 28(1):105-13. PubMed ID: 24840781
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.
Shigematsu T; Une Y; Ikejiri K; Kanda H; Fukagawa M; Akizawa T
Am J Nephrol; 2021; 52(6):496-506. PubMed ID: 34098559
[TBL] [Abstract][Full Text] [Related]
12. Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification.
Iida A; Kemmochi Y; Kakimoto K; Tanimoto M; Mimura T; Shinozaki Y; Uemura A; Matsuo A; Matsushita M; Miyamoto K
Am J Nephrol; 2013; 37(4):346-58. PubMed ID: 23548309
[TBL] [Abstract][Full Text] [Related]
13. Ferric citrate controls phosphorus and delivers iron in patients on dialysis.
Lewis JB; Sika M; Koury MJ; Chuang P; Schulman G; Smith MT; Whittier FC; Linfert DR; Galphin CM; Athreya BP; Nossuli AK; Chang IJ; Blumenthal SS; Manley J; Zeig S; Kant KS; Olivero JJ; Greene T; Dwyer JP;
J Am Soc Nephrol; 2015 Feb; 26(2):493-503. PubMed ID: 25060056
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy.
Fukagawa M; Kasuga H; Joseph D; Sawata H; Junge G; Moore A; Akiba T
Clin Exp Nephrol; 2014 Feb; 18(1):135-43. PubMed ID: 23670305
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients.
Aramwit P; Srisawadwong R; Supasyndh O
J Nephrol; 2012; 25(3):354-62. PubMed ID: 21748722
[TBL] [Abstract][Full Text] [Related]
17. Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis: Phase 3 Randomized Trial.
Akizawa T; Origasa H; Kameoka C; Tsukada J; Kuroishi K; Yamaguchi Y
Ther Apher Dial; 2016 Dec; 20(6):588-597. PubMed ID: 27896908
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of ferric citrate hydrate in serum phosphorus management of patients with chronic kidney disease: a long-term, real-world, observational, post-marketing surveillance study.
Yokoyama K; Hashimoto T; Okuda Y; Matsumoto Y; Ito K; Yamada R; Susai H; Nishino N
Clin Exp Nephrol; 2022 Jul; 26(7):688-699. PubMed ID: 35258721
[TBL] [Abstract][Full Text] [Related]
19. Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis.
Umanath K; Sika M; Niecestro R; Connelly C; Schulman G; Koury MJ; Lewis JB; Dwyer JP;
Hemodial Int; 2013 Jan; 17(1):67-74. PubMed ID: 22702490
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
